Teva plans to take over major chunk of migraine market Teva turns up its ambitions for migraine drug Ajovy, which is taking over a larger part of the US market than initially stated. Teva CEO Kåre Schultz | Photo: Amir Cohen/REUTERS / X02077 BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN Published: 11.02.21 at 15:42 In future years, more US patients will start treatment with Teva's migraine drug Ajovy. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch Board chair at Coloplast and Lundbeck warns against large pay rises Companies have a responsibility to help combat inflation by keeping pay rises in check during contract negotiations, says Lars Rasmussen. Ellab slapped with customs fine over US imports Danish medtech producer Ellab broke US customs rules and is now paying the price. China approves Y-mabs drug Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties. CEO gets "taste of own medicine" by participating in vaccine trial Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties. FDA approves Covid-19 jabs as boosters for infants The US Food and Drug Administration has approved the use of Moderna and Pfizer/Biontech’s coronavirus vaccines as boosters for children as young as six months old. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading FDA ruling to trigger royalty payments for Novo Nordisk Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes Danish agency joins competition authority chorus in criticizing Oticon Medical sale EU Commission proposes staggered transition to new medtech requirements after industry warnings FDA approves new sensor for insulin pens Related articles European Medicines Agency: Leaked documents have been manipulated Eli Lilly executive on crucial tirzepatide data: "It is a very exciting time"